Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer meeting 1 of the following criteria:
• * High-risk stage I disease, as defined by grade 3, aneuploid grade 1 or 2, or clear cell disease
• * Stage II, III, or IV disease
• Completed first-line therapy within the past 6 weeks
• * Received a platinum derivative (carboplatin or cisplatin) alone or in combination with other agents for 6-9 courses
• * Must have achieved complete response/no evidence of disease, partial response, or stabilization of disease after therapy
• No adenocarcinoma of unknown origin
• No known brain metastases or leptomeningeal disease
• PATIENT CHARACTERISTICS:
• Performance status
• ECOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Platelet count ≥ 100,000/mm\^3
• WBC ≥ 2,000/mm\^3
• Hepatic
• AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN in patients with known liver metastases)
• Bilirubin ≤ 1.5 times ULN
• Alkaline phosphatase ≤ 5 times ULN except in patients with known bone metastases
• PT and PTT ≤ 1.5 times ULN
• Renal
• Creatinine ≤ 2 times ULN
• Cardiovascular
• No myocardial infarction within past 6 months
• No second- or third-degree heart block without pacemaker
• Gastrointestinal
• No active peptic ulcer disease
• No gastrointestinal tract disease that would interfere with ability to take oral medications, affect absorption, or require parenteral nutrition
• No uncontrolled inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No significant dermatologic disease
• No inflammatory changes to the surface of the eye
• No history of allergic reaction to compounds of similar chemical composition as erlotinib
• No other significant medical condition or neurologic or psychiatric disorder
• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or cone-biopsied carcinoma in situ of the cervix
• No psychiatric illness or familial, geographic, or social situation that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior therapy targeting epidermal growth factor receptor
• No concurrent immunotherapy
• Chemotherapy
• See Disease Characteristics
• See Surgery
• No concurrent chemotherapy
• Endocrine therapy
• No concurrent hormonal therapy
• Radiotherapy
• No prior radiotherapy unless completed more than 5 years ago AND outside the abdomen/pelvis
• Surgery
• Interval debulking surgery after 3 courses of chemotherapy and second-look surgery at the end of chemotherapy allowed as per study EORTC-55971/NCIC OV13/Chorus
• Other
• No other prior or concurrent investigational agents
• No other concurrent anticancer treatment
• Concurrent participation in study EORTC-55971/NCIC-OV13/Chorus allowed